Geode Capital Management LLC raised its position in Esperion Therapeutics Inc (NASDAQ:ESPR) by 8.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 275,410 shares of the biopharmaceutical company’s stock after buying an additional 20,403 shares during the period. Geode Capital Management LLC owned 1.03% of Esperion Therapeutics worth $12,668,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ESPR. Russell Investments Group Ltd. boosted its position in Esperion Therapeutics by 598.3% in the third quarter. Russell Investments Group Ltd. now owns 12,422 shares of the biopharmaceutical company’s stock valued at $551,000 after buying an additional 10,643 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Esperion Therapeutics by 3.4% in the third quarter. JPMorgan Chase & Co. now owns 71,095 shares of the biopharmaceutical company’s stock valued at $3,155,000 after buying an additional 2,348 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Esperion Therapeutics by 5.6% in the third quarter. Bank of New York Mellon Corp now owns 117,796 shares of the biopharmaceutical company’s stock valued at $5,227,000 after buying an additional 6,212 shares in the last quarter. BlackRock Inc. boosted its position in Esperion Therapeutics by 4.1% in the third quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock valued at $83,367,000 after buying an additional 73,673 shares in the last quarter. Finally, Bamco Inc. NY boosted its position in Esperion Therapeutics by 528.9% in the third quarter. Bamco Inc. NY now owns 100,000 shares of the biopharmaceutical company’s stock valued at $4,437,000 after buying an additional 84,100 shares in the last quarter. Hedge funds and other institutional investors own 99.84% of the company’s stock.

Shares of ESPR stock opened at $42.89 on Thursday. Esperion Therapeutics Inc has a 1 year low of $33.06 and a 1 year high of $77.99. The company has a market cap of $1.13 billion, a PE ratio of -5.69 and a beta of 2.14.

A number of equities analysts have commented on ESPR shares. Stifel Nicolaus restated a “buy” rating and issued a $112.00 price target on shares of Esperion Therapeutics in a research report on Friday, March 29th. Cowen restated a “buy” rating and issued a $94.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, January 15th. ValuEngine lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Northland Securities restated a “buy” rating and issued a $65.00 price target on shares of Esperion Therapeutics in a research report on Friday, March 1st. Finally, BidaskClub upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 31st. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $73.69.

In other Esperion Therapeutics news, major shareholder Target N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was acquired at an average cost of $49.89 per share, with a total value of $2,494,500.00. Following the completion of the purchase, the insider now directly owns 3,522,964 shares in the company, valued at approximately $175,760,673.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Timothy M. Mayleben purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The shares were acquired at an average cost of $40.00 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer now owns 61,163 shares of the company’s stock, valued at $2,446,520. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 65,000 shares of company stock worth $3,155,550 and have sold 48,329 shares worth $2,280,206. 14.50% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/geode-capital-management-llc-has-12-67-million-position-in-esperion-therapeutics-inc-espr/2953968.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Story: Bid-Ask Spread

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.